Skeletal complications caused by osteoporosis or bone metastases are associated with
considerable pain, increased mortality, and reduced quality of life. Furthermore, such events …

Context Antiresorptive therapy significantly reduces fracture risk in patients with benign bone
disease and skeletal-related events (SREs) in patients with bone metastases (BM) …

Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side effect
of antiresorptive, and antiangiogenic drugs commonly used in cancer management. Despite …

Bisphosphonates (BPs) have been used as antiresorptive agents to treat patients with
osteoporosis or metastatic bone cancer, each of which is characterized by bone loss due to …

This study investigated the incidence, risk factors, and outcome of medication-related
osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents …

Root amputation, immunosuppressive therapy, mandibular tooth extraction, pre-existing
inflammation, and longer duration of treatment with bone-modifying agents were significantly …

Purpose Medication-related osteonecrosis of the jaw (MRONJ) is a rare but severe adverse
event of antiresorptive agents. However, the precise prevalence and factors associated with …

Background Medication-related osteonecrosis of the jaw (MRONJ) is a serious debilitating
disease caused by anti-resorption and anti-angiogenesis drugs, significantly affecting …

Tooth extraction in patients receiving bisphosphonates is thought to be a risk factor for
osteonecrosis of the jaw (ONJ); however, ONJ did not develop, even when tooth extraction …

Objective This manuscript aims to provide a comprehensive review of the current knowledge
in the pathophysiology, diagnosis, prevention, and other relevant forensic and clinical …